Literature DB >> 322907

Clinical pharmacokinetics of digoxin.

E Iisalo.   

Abstract

About 70 to 80% of an oral dose of digoxin is absorbed, mainly in the proximal part of the small intestine. The degree of binding to serum albumin is 20 to 30%. Digoxin is extensively distributed in the tissues, as reflected by the large volume of distribution. High concentrations are found in the heart and kidneys, but the skeletal muscles form the largest digoxin storage. The half-life of elimination in healthy persons varies between 26 and 45 hours. The main route of elimination is renal excretion of digoxin, which is closely correlated with the glomerular filtration rate. In addition, some tubular secretion and perhaps tubular reabsorption occurs. Nearly all of the digoxin in the urine is excreted unchanged, with a small part as active metabolites. The clinical significance of dihydrodigoxin as a metabolite remains to be resolved. About 25 to 28% of digoxin is eliminated by nonrenal routes. Biliary excretion may rise up to 30% of a given dose, but the enterohepatic cycle seems to be of minor importance. The pharmacodynamic effects of digoxin, including toxic symptoms, are correlated with the uptake of digoxin in the heart after a single dose and with the steady state serum digoxin concentration during maintenance therapy. Impaired kidney function is the most important condition with an influence on the pharmacokinetics of digoxin. In addition to the renal clearance of creatinine, the biovailability of the digoxin formulation used, the volume of distribution, the amount of extrarenal clearance, body weight and serum albumin concentration, are other factors which may modify the serum level of digoxin. Certain drug interactions may also occur during the absorptive phase. Exact prediction of serum digoxin concentrations by various dosage calculations has not succeeded. Since many factors may influence the sensitivity of the myocardium to digoxin, measurement of serum digoxin levels in only one, but a useful criterion, when making clinical decisions about adjustment of digoxin dosage.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 322907     DOI: 10.2165/00003088-197702010-00001

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  111 in total

1.  A METHOD FOR MEASURING PLASMA LEVELS OF DIGITALIS GLYCOSIDES.

Authors:  J M LOWENSTEIN
Journal:  Circulation       Date:  1965-02       Impact factor: 29.690

Review 2.  Appraisal of digoxin bioavailability and pharmacokinetics in relation to cardiac therapy.

Authors:  J G Wagner
Journal:  Am Heart J       Date:  1974-08       Impact factor: 4.749

3.  Elimination of digoxin during maintenance haemodialysis.

Authors:  E Iisalo; J Forsström
Journal:  Ann Clin Res       Date:  1974-08

4.  Treatment of digoxin intoxication.

Authors:  G Härtel; V Manninen; P Reissell
Journal:  Lancet       Date:  1973-07-21       Impact factor: 79.321

5.  Effects of maintenance digoxin therapy on systolic time intervals and serum digoxin concentrations.

Authors:  N H Carliner; C A Gilbert; A W Pruitt; L I Goldberg
Journal:  Circulation       Date:  1974-07       Impact factor: 29.690

6.  Identification by gas chromatography-mass spectroscopy of dihydrodigoxin--a metabolite of digoxin in man.

Authors:  E Watson; D R Clark; S M Kalman
Journal:  J Pharmacol Exp Ther       Date:  1973-02       Impact factor: 4.030

7.  The absorption of orally administered (12 - 3 H)digoxin in man.

Authors:  B Beermann; K Hellström; A Rosén
Journal:  Clin Sci       Date:  1972-10       Impact factor: 6.124

8.  Human serum and myocardium digoxin.

Authors:  G Härtel; K Kyllönen; E Merikallio; K Ojala; V Manninen; P Reissell
Journal:  Clin Pharmacol Ther       Date:  1976-02       Impact factor: 6.875

Review 9.  Drug metabolism in thyroid disease.

Authors:  M Eichelbaum
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

10.  Concentrations of digoxin in plasma and urine in neonates, infants, and children with heart disease.

Authors:  G Wettrell; K E Andersson; A Bertler; N R Lundström
Journal:  Acta Paediatr Scand       Date:  1974-09
View more
  73 in total

Review 1.  Therapeutic drug monitoring of antiarrhythmic drugs.

Authors:  Gesche Jürgens; Niels A Graudal; Jens P Kampmann
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 2.  Therapeutic drug monitoring in saliva. An update.

Authors:  R K Drobitch; C K Svensson
Journal:  Clin Pharmacokinet       Date:  1992-11       Impact factor: 6.447

3.  Impact of reduced P-glycoprotein function on digoxin concentrations in patients with dementia.

Authors:  Izna Ali; Daniel Guidone; Joseph A Nicolazzo; Kim L R Brouwer
Journal:  Br J Clin Pharmacol       Date:  2019-08-19       Impact factor: 4.335

4.  Evaluation of a Potential Clinical Significant Drug-Drug Interaction between Digoxin and Bupropion in Cynomolgus Monkeys.

Authors:  Yang Shen; Yang Yu; Wei Lai; Shuai Li; Zixuan Xu; Jiejing Jin; Xia Yan; Han Xing; Xijing Chen; Aizhen Xiong; Chunhua Xia; Jiake He; Kui Hong
Journal:  Pharm Res       Date:  2018-11-06       Impact factor: 4.200

Review 5.  Therapeutic drug monitoring in saliva.

Authors:  M Danhof; D D Breimer
Journal:  Clin Pharmacokinet       Date:  1978 Jan-Feb       Impact factor: 6.447

6.  Prediction of digoxin dose requirements.

Authors:  S M Dobbs; G E Mawer
Journal:  Clin Pharmacokinet       Date:  1977 Jul-Aug       Impact factor: 6.447

7.  Clinical pharmacokinetics of digitoxin.

Authors:  D Perrier; M Mayersohn; F I Marcus
Journal:  Clin Pharmacokinet       Date:  1977 Jul-Aug       Impact factor: 6.447

Review 8.  Impact of obesity on drug metabolism and elimination in adults and children.

Authors:  Margreke J E Brill; Jeroen Diepstraten; Anne van Rongen; Simone van Kralingen; John N van den Anker; Catherijne A J Knibbe
Journal:  Clin Pharmacokinet       Date:  2012-05-01       Impact factor: 6.447

9.  Comparative studies of the protein binding of digoxin and its metabolites.

Authors:  P H Hinderling
Journal:  Agents Actions       Date:  1977-09

Review 10.  The effect of respiratory disorders on clinical pharmacokinetic variables.

Authors:  A M Taburet; C Tollier; C Richard
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.